Olav Mella

Bergen, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Correction: SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis.

Correction: SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis.

Journal: Journal of translational medicine
Published: August 14, 2025

Expert perspectives on Myalgic encephalomyelitis/chronic fatigue syndrome - Insights from the 3rd International Conference of the Charité Fatigue Center.

Expert perspectives on Myalgic encephalomyelitis/chronic fatigue syndrome - Insights from the 3rd International Conference of the Charité Fatigue Center.

Journal: Autoimmunity reviews
Published: August 12, 2025

Charting the circulating proteome in ME/CFS using cross-system profiling to uncover mechanistic insights.

Charting the circulating proteome in ME/CFS using cross-system profiling to uncover mechanistic insights.

Journal: Cell reports. Medicine
Published: May 28, 2025

Killer cell immunoglobulin-like receptor (KIR) alleles suggested to be associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Killer cell immunoglobulin-like receptor (KIR) alleles suggested to be associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Journal: Brain, behavior, and immunity
Published: May 14, 2025

SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis.

SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis.

Journal: Journal of translational medicine
Published: April 10, 2025

Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-a clinical pilot study.

Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-a clinical pilot study.

Journal: Frontiers in medicine
Published: April 07, 2025

Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome - State of the art: Report of the 2nd international meeting at the Charité Fatigue Center.

Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome - State of the art: Report of the 2nd international meeting at the Charité Fatigue Center.

Journal: Autoimmunity reviews
Published: September 01, 2023

Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Journal: PloS one
Published: July 05, 2023

Gastric dysmotility and gastrointestinal symptoms in myalgic encephalomyelitis/chronic fatigue syndrome.

Gastric dysmotility and gastrointestinal symptoms in myalgic encephalomyelitis/chronic fatigue syndrome.

Journal: Scandinavian journal of gastroenterology
Published: February 02, 2023

Endothelial dysfunction in ME/CFS patients.

Endothelial dysfunction in ME/CFS patients.

Journal: PloS one
Published: July 05, 2022

Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients.

Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients.

Journal: PloS one
Published: April 06, 2022

Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas.

Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas.

Journal: Cancers
Published: January 04, 2022
Showing 1-12 of 33

Last Updated: 09/26/2026